Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism

Li, Meixuan; Li, Jing; Wang, Xiaoqin; Xu, Hui; Wang, Qi; Xie, Song; Yan, Peijing; Tian, Jinhui; Li, Jianfeng; Xie, Ping; Yang, Kun; Yao, Liang

doi:10.1002/14651858.cd010957.pub3

Cited by 7 publications

(2 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a Cochrane meta-analysis, it was found that there were no differences between DOACs and conventional anticoagulation of recurrent VTE. However, the evidence was moderate or low [98]. When discontinuing the anticoagulant therapy, patients with a metastatic disease are at greater risk of VTE recurrence at 6 and 12 months; however, with regard to incidental VTE, the risk is lower in this time period [99].…”

Section: Could Doacs Be Used As a Substitute For Classic Anticoagulan...mentioning

confidence: 93%

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review

Górnicki

Bułdyś

Zielińska³

et al. 2023

Cancers

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is an important aspect in cancer patients. There are various pharmacological methods used for thrombotic event treatment. DOACs (direct-acting oral anticoagulants) are gaining popularity among both physicians and researchers and are slowly starting to replace VKAs (vitamin K antagonists), thus becoming a substitute or alternative option for LMWHs (low-molecular-weight heparins). In this article, we present DOACs’ main therapeutic advantages and disadvantages in patients with cancer. The only major concern with using DOACs is the higher risk of bleeding; however, there are discrepancies in this matter. There are still some types of cancer for which DOACs are not recommended. Specific cancer types may influence the efficacy of DOAC therapy. Additionally, race and ethnicity may affect therapy in cancer patients with DOACs. A sizeable number of clinical trials are focused on comparing DOACs with other anticoagulants. The current guidelines of different scientific associations are not unanimous in their DOAC assessments. There is still a need for more evidence of DOACs’ potential advantages over other methods of anticoagulation in cancer patients to facilitate their position in this recommendation. This literature review presents the current state of knowledge about the use of DOACs in patients with neoplastic growth.

show abstract

Section: Could Doacs Be Used As a Substitute For Classic Anticoagulan...mentioning

confidence: 93%

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review

Górnicki

Bułdyś

Zielińska³

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Phase III trials with DOACs for the treatment of VTE did not require any specific risk stratification in patients entering the studies for index PE. 5 6 7 8 42 43 The radiological extension of emboli was reported in all the studies, the proportion of patients with extensive PE varying from 24 to 47%. 44 In a post hoc analysis including 3,319 patients with PE from the Hokusai-VTE, NT-proBNP was increased in 30 and 32% of patients randomized to edoxaban and warfarin, respectively.…”

Section: Doacs In the Treatment Of Pe Patients At Intermediate To Hig...mentioning

confidence: 94%

Direct Oral Anticoagulants for Pulmonary Embolism

Pizzi,

Cimini,

Ageno

et al. 2024

Hamostaseologie

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism (PE), with the DOACs being now recommended as the first therapeutic choice. Additional research has contributed to identifying low-risk PE patients who can benefit from outpatient management or from early discharge from the emergency department with DOAC treatment. There is evidence to support the use of DOACs in intermediate-risk PE patients as well as in high-risk patients receiving thrombolytic treatment. The use of DOACs has also been proven to be safe and effective in special populations of PE patients, such as patients with renal impairment, liver impairment, and cancer.

show abstract

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Wang

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism

Cited by 7 publications

References 174 publications

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review

Direct Oral Anticoagulants for Pulmonary Embolism

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Contact Info

Product

Resources

About